Antimicrobial resistance threatens lung cancer care because almost every stage of treatment, from surgery to chemotherapy, relies on antibiotics that work. New data from the European Centre for Disease Prevention and Control (ECDC), published on European Antibiotic Awareness Day, show that Europe is still behind on several of its 2030 targets, with bloodstream infections caused by carbapenem-resistant Klebsiella pneumoniae up 72% since 2019.
This article sets out what the new figures show, why people with lung cancer are particularly exposed to resistant infections, and what European action the evidence points to.
Key points
Europe is off track on its resistance targets. Since 2019, carbapenem-resistant Klebsiella pneumoniae bloodstream infections have risen 72% and third-generation cephalosporin-resistant E. coli infections 16.4% (ECDC, 2026).
People with cancer are hit harder. A 2025 study in The Lancet Oncology found people with cancer had resistant infections at up to three times the rate of people without cancer.
Lung cancer care depends on effective antibiotics. Surgery, chemotherapy and the management of treatment side effects all rely on being able to prevent and treat infection.
Data on lung cancer is thin. Most evidence on resistance in cancer comes from blood cancers, and resistance is rarely recorded when people with cancer die.
What do the 2026 ECDC figures show?
The EU has met one of its five 2030 antimicrobial resistance targets and is behind on the other four. ECDC Director Pamela Rendi-Wagner said Europe remains behind on several targets, and called for faster genomic surveillance so that countries can see how resistant bacteria spread and act sooner.
The targets were set by the Council of the EU in June 2023, using 2019 as the baseline. The latest figures cover 2025:
Total antibiotic use: down 5% (from 19.9 to 18.9 defined daily doses per 1,000 people per day), against a 20% reduction target.
Antibiotics from the WHO Access group: 62.5% of use, up from 61.1%, against a target of at least 65%.
MRSA bloodstream infections: down 19% (from 5.63 to 4.56 per 100,000 people), meeting the 15% reduction target.
Third-generation cephalosporin-resistant E. coli bloodstream infections: up 16.4% (from 10.42 to 12.13 per 100,000 people), against a 10% reduction target.
Carbapenem-resistant Klebsiella pneumoniae bloodstream infections: up 72% (from 2.18 to 3.75 per 100,000 people), against a 5% reduction target.
Source: ECDC, Progress towards 2030 targets to combat antimicrobial resistance, 2026 update (EU data for 2025), published 18 November 2026.
Even the MRSA result is fragile: ECDC notes that rises over the past two years threaten that progress. ECDC also reports more carbapenem-resistant E. coli in both healthcare settings and the community.
The infections that are rising fastest are serious bloodstream infections caused by bacteria that are increasingly hard to treat. These are the infections people with weakened immune systems, including many people having cancer treatment, are least able to fight.
Why are people with lung cancer more vulnerable to infection?
People with lung cancer face a higher risk of infection because both the disease and its treatment weaken the body's defences. Chemotherapy, some targeted therapies and steroids all reduce immunity, while frequent hospital visits and devices such as urinary catheters and intravenous lines add exposure to bacteria.
A 2026 European Cancer Organisation report, Treating the Whole Patient, highlights that people with cancer are two to five times more likely to develop a healthcare-associated infection. We covered the report's findings in detail in our article on why people with lung cancer face a higher risk of hospital infections.
Lung cancer brings particular risks because the disease affects the organ where many serious infections start. A Danish study of 7,479 people who had lung cancer surgery between 1995 and 2011 found that 3.6% developed pneumonia within 30 days. Previous pneumonia and chronic lung disease were among the strongest risk factors, and people who developed pneumonia had higher mortality over the following year (21.6% compared with 16.8%).
How common are drug-resistant infections in people with cancer?
People with cancer have drug-resistant infections far more often than people without cancer. A study by the Cancer and AMR Consortium, published in The Lancet Oncology in May 2025, analysed more than 1.6 million bacterial samples from 198 outpatient sites in the United States. People with cancer had resistant infections at rates up to three times higher, and some combinations of bacteria and infection site were more than five times more common.
A companion scoping review in the same journal looked at 274 studies from 52 countries. It found 35% of bacterial infections in people with blood cancers involved resistant bacteria, and 65% of the 81 studies that reported deaths linked resistant infections to higher mortality.
There is much less evidence on lung cancer specifically. One of the few studies comes from University Cancer Center Frankfurt in Germany, which followed 295 people with non-small cell lung cancer diagnosed between 2012 and 2016. The 8.1% who carried multidrug-resistant bacteria had a median survival of 7.8 months, compared with 23.9 months for those who did not, and were more likely to die from infection. The study was small, single-centre and retrospective, and the authors say the results need confirming in larger groups.
Which parts of lung cancer care depend on effective antibiotics?
Nearly every part of lung cancer care depends on being able to prevent and treat infection. Without effective antibiotics, treatments that are routine today become far riskier.
Surgery. Surgery offers the best chance of cure for many people diagnosed with early-stage lung cancer. As lung cancer screening expands across Europe, more people will be diagnosed early enough to be offered an operation, and safe surgery relies on antibiotics to prevent and treat pneumonia and wound infections.
Chemotherapy. Chemotherapy can cause neutropenia, a sharp fall in the white blood cells that fight infection. Fever during neutropenia needs urgent antibiotic treatment, and resistance makes it more likely that the first antibiotic will fail. In a Portuguese study of 42 admissions for neutropenic fever in people with lung cancer, first-line antibiotics failed in just over a quarter of cases.
Supportive care. Catheters, intravenous lines and repeated hospital stays are part of treatment for many people with lung cancer. Each is a route for infection.
Speaking at the European Cancer Organisation roundtable behind its 2026 report, Antonella Cardone of Cancer Patients Europe warned that, if left unaddressed, antimicrobial resistance could make some routine cancer treatments unviable by 2030.
What does Europe need to do?
ECDC is calling for a coordinated package of infection prevention and control, antibiotic stewardship, laboratory capacity and stronger surveillance. At the point of care, that means reliable hand hygiene, correct use of protective equipment, fast identification and isolation of people carrying resistant bacteria, and effective cleaning. ECDC also says healthcare managers need enough infection control staff, diagnostic capacity and isolation rooms.
From a lung cancer perspective, the evidence points to four further priorities:
Count resistance in cancer. Surveillance should show how often resistant infections affect people with cancer. Antonella Cardone of Cancer Patients Europe has pointed out that resistance is rarely recorded on death certificates, so its true toll is hidden.
Build infection prevention into cancer pathways. This includes reducing unnecessary urinary catheterisation, one of the European Cancer Organisation's key recommendations.
Include antimicrobial resistance in national cancer plans. Cancer control planning and the implementation of Europe's Beating Cancer Plan should address infection risk directly.
Fund research on lung cancer. Most evidence comes from blood cancers. Larger European studies in people with lung cancer would show where the risks are greatest.
Member organisations can find national figures in ECDC's new country infographics, published for all 27 EU Member States, and use them to raise antimicrobial resistance with health ministries and cancer services.
Frequently asked questions
Why is antimicrobial resistance a particular concern for people with lung cancer?
Lung cancer treatment often weakens the immune system, and the lungs are a common site of serious infection. Surgery and chemotherapy both rely on antibiotics to prevent and treat infection, so resistance makes standard care riskier.
Is the EU on track to meet its 2030 antimicrobial resistance targets?
No. ECDC's 2026 update shows the EU has met its target for MRSA but is behind on the other four, with carbapenem-resistant Klebsiella pneumoniae bloodstream infections up 72% since 2019.
Are people with cancer more likely to get drug-resistant infections?
Yes. A 2025 study in The Lancet Oncology found people with cancer had resistant infections at up to three times the rate of people without cancer, based on more than 1.6 million samples from the United States.
Where can I find antimicrobial resistance data for my country?
ECDC publishes a country infographic for each EU Member State on its European Antibiotic Awareness Day website. The 2026 editions were published on 18 November 2026 and show progress on each of the five targets.
Antimicrobial resistance is rising in Europe, and the infections growing fastest are those people having cancer treatment are least able to fight. People with cancer already face resistant infections at up to three times the rate of others, yet data on lung cancer remain scarce. Safe surgery, chemotherapy and supportive care all depend on antibiotics that work. Protecting them needs infection prevention built into cancer care, better data on resistance in cancer, and antimicrobial resistance written into Europe's cancer plans.
Read our earlier article on why people with lung cancer face a higher risk of hospital infections for the European Cancer Organisation's full recommendations.
About Lung Cancer Europe
Lung Cancer Europe is a pan-European advocacy organisation working for equal access to high-quality lung cancer care across Europe. Our members are national lung cancer advocacy organisations, and we bring their evidence and experience to European policymakers. Through our annual Lung Cancer Europe Reports, our Charter and the Get Checked! campaign, we work to improve diagnosis, treatment and support for everyone affected by lung cancer.
References
1. European Centre for Disease Prevention and Control. Urgent action needed to safeguard the effectiveness of antibiotics. 18 November 2026. Press release
2. European Centre for Disease Prevention and Control. Infographic: Antimicrobial resistance targets, how is the EU doing? 2026 update. 18 November 2026. Infographic
3. Council of the European Union. Council Recommendation on stepping up EU actions to combat antimicrobial resistance in a One Health approach (2023/C 220/01). 13 June 2023.
4. Cancer and AMR Consortium. Antimicrobial resistance in people with cancer in US outpatient settings. The Lancet Oncology, 1 May 2025. Summary
5. Sallah YH, Bratti VF, Rafinejad-Farahani B, et al. Antimicrobial resistance in patients with haematological malignancies: a scoping review. The Lancet Oncology, 2025. Abstract
6. Stratmann JA, Lacko R, Ballo O, et al. Colonization with multi-drug-resistant organisms negatively impacts survival in patients with non-small cell lung cancer. PLoS ONE, 2020;15(11):e0242544. Article
7. Simonsen DF, Søgaard M, Bozi I, Horsburgh CR, Thomsen RW. Risk factors for postoperative pneumonia after lung cancer surgery and impact of pneumonia on survival. Respiratory Medicine, 2015;109(10):1340-1346. Article
8. Pimenta AC, Raimundo S, Conde B, et al. Neutropenic fever in lung cancer: clinical aspects related to mortality and antibiotic failure. Chinese Journal of Lung Cancer, 2021;24(11):764-769. Article
9. European Cancer Organisation. Treating the Whole Patient: Addressing often overlooked aspects of cancer care. 21 April 2026. Report